V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

September 27, 2026

Study Completion Date

February 27, 2027

Conditions
ImmunodeficienciesPrimary Immunodeficiencies (PID)Agammaglobulinemia
Interventions
BIOLOGICAL

Intravenous immunoglobulin (IVIG)

"The investigational product is V-IMMUNE®, a 5% human normal immunoglobulin I.P. (5 g/100 mL) manufactured from qualified human plasma for intravenous use. Each vial contains human immunoglobulin at 50 g/L, maltose at 100 g/L, and water for injection. The 5% Human Immunoglobulin Solution for Intravenous Administration (I.P.) is a sterile and pyrogen-free preparation of human normal immunoglobulin in a single-dose form for intravenous administration. Each 10 mL, 50 mL, or 100 mL vial contains 0.5 g, 2.5 g, or 5 g of human normal immunoglobulin, respectively, and is produced from qualified human plasma using membrane filtration and a combination of chromatographic steps and viral inactivation procedures. The IgA content does not exceed 2 mg/mL.~This manufacturing process uses plasma collected from donors who undergo screening according to guidelines set by regulatory authorities. Blood is tested for all mandatory infectious diseases."

Trial Locations (1)

50070-902

RECRUITING

IMIP Centro de Pesquisa, Recife

All Listed Sponsors
collaborator

Hospital do Coracao

OTHER

lead

On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.

OTHER